Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Retained Earnings (2017 - 2025)

Historic Retained Earnings for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to -$931.2 million.

  • Sutro Biopharma's Retained Earnings fell 3034.24% to -$931.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$931.2 million, marking a year-over-year decrease of 3034.24%. This contributed to the annual value of -$786.9 million for FY2024, which is 4066.1% down from last year.
  • Per Sutro Biopharma's latest filing, its Retained Earnings stood at -$931.2 million for Q3 2025, which was down 3034.24% from -$874.3 million recorded in Q2 2025.
  • Sutro Biopharma's 5-year Retained Earnings high stood at -$258.2 million for Q1 2021, and its period low was -$931.2 million during Q3 2025.
  • Its 5-year average for Retained Earnings is -$549.5 million, with a median of -$541.2 million in 2023.
  • Data for Sutro Biopharma's Retained Earnings shows a peak YoY increase of 1991.83% (in 2021) and a maximum YoY decrease of 7543.03% (in 2021) over the last 5 years.
  • Over the past 5 years, Sutro Biopharma's Retained Earnings (Quarter) stood at -$333.4 million in 2021, then tumbled by 35.75% to -$452.6 million in 2022, then dropped by 23.59% to -$559.4 million in 2023, then tumbled by 40.66% to -$786.9 million in 2024, then dropped by 18.34% to -$931.2 million in 2025.
  • Its Retained Earnings stands at -$931.2 million for Q3 2025, versus -$874.3 million for Q2 2025 and -$862.8 million for Q1 2025.